Raelene Nick Endersby Gottardo R NG BSc (Hons) PhD MBChB FRACP PhD Brainchild Fellow; Co-Head, Brain Tumour Research Co-Head, Brain Tumour Research raelene.endersby@telethonkids.org.au nicholas.gottardo@telethonkids.org.au Co-Head, Brain Tumour ...

• Telethon Kids Institute
• Projects

Our case demonstrates that AML therapy, without HSCT, can be sufficient to treat this rare disease in children. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2013
• March 2013

We hypothesized that reactivation of p53 by inhibition of its negative regulator will result in p53-mediated growth arrest and apoptosis. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2012
• February 2012

This article summarizes data from collaborative group and institutional trials that have advanced the science of pediatric brain tumors. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2015
• August 2015

Childhood acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and brain tumors (CBTs) are the leading cause of cancer death in... ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2013
• January 2013

Tumor cell death potentially engages with the immune system. However, the efficacy of anti-tumor chemotherapy may be limited by tumor-driven... ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2009
• August 2009

The epidemiological, prognostic, and therapeutic features of child and adolescent meningioma are poorly defined... ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2011
• November 2011

We undertook a retrospective review of children diagnosed with acute lymphoblastic leukemia (ALL) and treated with modern COG protocols to determine... ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2015
• June 2015

Present a valuable resource for drug discovery and have identified ROM as a promising therapeutic for MLL-rearranged iALL ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2016
• January 2016

Medulloblastoma is the most common childhood brain cancer. Mainstay treatments of radiation and chemotherapy have not changed in decades and new treatment approaches are crucial for the improvement of clinical outcomes. To date, immunotherapies for medulloblastoma have been unsuccessful, and studies investigating the immune microenvironment of the disease and the impact of current therapies are limited. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2022
• March 2022

Pediatric acute lymphoblastic leukemia (ALL) therapy is accompanied by treatment-related toxicities (TRTs) and impaired quality of life. In Australia and New Zealand, children with ALL are treated with either Children's Oncology Group (COG) or international Berlin-Frankfurt-Munster (iBFM) Study Group-based therapy. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2022
• September 2022

Embryonal tumours with multi-layered rosettes (ETMRs) are a newly recognised, rare paediatric brain tumour with alterations of the C19MC microRNA locus. Due to varied diagnostic practices and scarce clinical data, disease features and determinants of outcomes for these tumours are poorly defined. We did an integrated clinicopathological and molecular analysis of primary ETMRs to define clinical phenotypes, and to identify prognostic factors of survival and key treatment modalities for this orphan disease. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• November 2021